Stockreport

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Harpoon Therapeutics, Inc.  (HARP) 
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm Check Earnings Report
PDF Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year [Read more]